Latest News

Oslo, Norway, 6 December 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 3 December 2021 regarding exercise of share options.

Oslo, Norway, 3 December 2021: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 3 December 2021 exercised a total of 30 000 options distributed as follows:

Press Release – Oslo, Norway, 23 November 2021, Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl will present a corporate overview and host 1-on-1 meetings with investors at the Piper Sandler 33^rd Annual Healthcare conference, being held virtually November 29 through December 2, 2021.

Oslo, Norway, 17 November 2021: Photocure ASA (OSE:PHO) today reported Hexvix^®/Cysview^® revenues of NOK 86.7 million in the third quarter of 2021 (Q3 2020: NOK 49.6), and EBITDA of NOK -0.2 million (-5.4), following the continued successful launch in markets previously operated by Ipsen Pharma SAS. The Company plans to increase its investment in commercial activities to further penetrate the large potential market opportunity for its bladder cancer treatment.

Oslo, Norway, 9 November 2021: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2021 financial results on Wednesday 17 November 2021 at 07:30 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.

Press Release – Oslo, Norway, September 15, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces a clinical data presentation and highlights from the 2021 American Urological Association Annual Congress (AUA2021), which was held virtually September 10-13, 2021. During the program, new results from a study using Blue Light Cystoscopy (BLC^®) with Cysview^® in the surveillance setting were reported in a podium presentation, and separately, BLC with Cysview was discussed in an Expert Presentation on Surgical Techniques.

Press Release – Oslo, Norway September 8, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, announces that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl are scheduled to present corporate overviews and participate in meetings with investors at two upcoming conferences: the H.C. Wainwright 23^rd Annual Global Investment Conference to be held September 13-15, 2021, and the Danske Bank Securities Life Science Seminar on September 20, 2021.

Oslo, Norway, 1 September 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 31 August 2021 regarding exercise of share options and sale of own shares, together with primary insider notifications.

Oslo, Norway, 1 September 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 30 August 2021 regarding a share capital increase following the exercise of share options.

Press Release – Oslo, Norway, September 1, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Anders Neijber as Vice President, Global Medical Affairs and Clinical Development, effective September 1st, 2021.

Oslo, Norway, 31 August 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 30 August 2021 regarding exercise of share options.

Oslo, Norway, 30 August 2021: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 30 August 2021 exercised a total of 25,500 options distributed as follows:

Press release – Oslo, Norway, 25 August 2021: Photocure ASA (Photocure, PHO: OSE) announces that it has reached agreement with BioSyent Pharma Inc. (“BioSyent”) to reacquire the marketing and distribution rights to Cysview^® in Canada. The parties entered into a final agreement today, stipulating that commercial rights will transfer to Photocure on January 1^st, 2022. The reacquisition of marketing and distribution rights enables Photocure’s direct management of the Cysview brand in Canada and consolidates the territory into Photocure’s existing U.S. business to form its North America sales segment.

Oslo, Norway, 23 August 2021 - The board of directors in Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Press Release – Oslo, Norway August 23, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients,  announces that President and Chief Executive Officer, Daniel Schneider and Chief Financial Officer, Erik Dahl are scheduled to present a corporate overview and participate in meetings with investors at the Nordea Annual Small & Mid Cap Days 2021 conference to be held virtually August 24-26, 2021.

Oslo, Norway, August 16, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that the Marketing Authorization for Hexvix^® in Chile has been granted. Photocure’s partner and exclusive distributor, Genotests SpA, received the official regulatory approval by the Instituto de Salud Pública de Chile on August 12th.